BNO News: Novamind to Host Bionomics’ PREVAIL Trial for Acute Treatment of Social Anxiety Disorder - 10th May 2022, 10:00pm

[annb0t]

TORONTO, ON / ACCESSWIRE / May 10, 2022 / Novamind Inc.(CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced it has been selected to host a clinical trial for the acute treatment of social anxiety disorder (SAD), an understudied and common mental health condition that affects nearly 15 million American adults.1 The phase II randomized clinical study for the acute treatment of SAD (the "PREVAIL Trial") is...

>>> Read more: Novamind to Host Bionomics’ PREVAIL Trial for Acute Treatment of Social Anxiety Disorder